Chardan Capital Initiates Coverage On Zura Bio with Buy Rating, Announces Price Target of $14
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Matthew Barcus initiates coverage on Zura Bio (NASDAQ:ZURA) with a Buy rating and announces a price target of $14.
June 14, 2023 | 10:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital initiates coverage on Zura Bio with a Buy rating and a price target of $14.
Chardan Capital's initiation of coverage on Zura Bio with a Buy rating and a price target of $14 indicates a positive outlook for the stock. This news is likely to attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100